BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 14, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Lorvotuzumab mertansine regulatory update

FDA granted Orphan Drug designation for ImmunoGen's lorvotuzumab mertansine to treat multiple myeloma (MM). The CD56 targeting antibody with DM1...

Read the full 88 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >